DUBLIN--(BUSINESS WIRE)--The "Research Antibodies and Reagents Market - Global Opportunity Analysis and Industry Forecast (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
Global research antibodies and reagents market is expected to reach USD 13,276.5 million by 2023, at a CAGR of 6.5% during the forecast period of 2018 to 2023.
The report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges in the market dynamics segment. Rising proteomics and genomics research studies, increasing funding for research activities, and growing industry-academia collaborations are majorly driving the global research antibodies and reagents market. However, high cost and time related to development of potential antibodies hinders the growth of this market to some extent.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017).
Scope of the report
Market by Product:
- Reagents
- Media and Serum
- Stains and Dyes
- Probes
- Buffers
- Solvents
- Enzymes
- Proteins
- Others
Research Antibodies Market, by Type
- Primary Antibodies
- Secondary Antibodies
- ResearchAntibodies Market, by Production
- Monoclonal Antibodies
- Polyclonal Antibodies
- Antibodies Fragments
Research Antibodies Market, by Source
- Mouse
- Rabbit
- Others
Research Antibodies Market, by Research Areas
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Immunology
- Neurology
- Stem Cell
- Others
Market by Technology:
- Western Blotting
- Immunofluorescence
- Immunosorbent Assays
- Flow Cytometry
- Immunohistochemistry
- Immunoprecipitation
- Others
Market by Application:
- Proteomics
- Drug Discovery & Development
- Genomics
Market by End User:
- Pharmaceutical and Biotechnology Industry
- Academic and Research Institutes
- Contract Research Organizations
Companies Mentioned
- GE Healthcare (U.S.)
- Merck & Co. Inc.(U.S.)
- Thermo Fisher Scientific Inc.(U.S.)
- Amgen Inc.(U.S.)
- Sanofi (France)
- F. Hoffmann La-Roche Ltd (Switzerland)
- Rockland Immunochemicals Inc.(U.S.)
- Johnson & Johnson (U.S.)
- Agilent Technologies Inc.(U.S.)
- Eli Lilly and Company (U.S.)
- Becton Dickinsonand Company (U.S.)
- Danaher Corporation (U.S.)
- PerkinElmer Inc.(U.S.)
- GenScript Biotech Corporation (U.S.)
- Lonza (Switzerland)
- Bio-Techne Corporation (U.S.)
- Bio-Rad Laboratories Inc.(U.S.)
- Teva Pharmaceutical Industries Limited (Israel)
- Santa Cruz Biotechnology Inc.(U.S.)
- BioLegend Inc.(U.S.)
- Abcam PLC (U.K.)
- Cell Signaling Technology Inc.(U.S.)
For more information about this report visit https://www.researchandmarkets.com/research/j6hgg3/research?w=4
